Technical Analysis for CLLS - Cellectis S.A.

Grade Last Price % Change Price Change
grade F 22.0 -2.27% -0.51
CLLS closed down 2.27 percent on Friday, November 16, 2018, on 2.64 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CLLS trend table...

Date Alert Name Type % Chg
Nov 16 New 52 Week Closing Low Bearish 0.00%
Nov 16 Calm After Storm Range Contraction 0.00%
Nov 16 Doji - Bullish? Reversal 0.00%
Nov 16 Lower Bollinger Band Walk Weakness 0.00%
Nov 16 New 52 Week Low Weakness 0.00%
Nov 16 Stochastic Reached Oversold Weakness 0.00%
Nov 16 Below Lower BB Weakness 0.00%
Nov 16 Down 3 Days in a Row Weakness 0.00%
Nov 16 Down 4 Days in a Row Weakness 0.00%
Nov 16 Down 5 Days in a Row Weakness 0.00%

Older signals for CLLS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company's products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.
Is CLLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 38.85
52 Week Low 21.29
Average Volume 162,414
200-Day Moving Average 29.2618
50-Day Moving Average 26.851
20-Day Moving Average 25.48
10-Day Moving Average 25.438
Average True Range 0.9467
ADX 23.89
+DI 12.4832
-DI 47.5571
Chandelier Exit (Long, 3 ATRs ) 24.9899
Chandelier Exit (Short, 3 ATRs ) 24.1301
Upper Bollinger Band 28.1781
Lower Bollinger Band 22.7819
Percent B (%b) -0.14
BandWidth 21.178179
MACD Line -0.8526
MACD Signal Line -0.4884
MACD Histogram -0.3641
Fundamentals Value
Market Cap 787.37 Million
Num Shares 35.8 Million
EPS -2.30
Price-to-Earnings (P/E) Ratio -9.57
Price-to-Sales 23.25
Price-to-Book 4.09
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.65
Resistance 3 (R3) 23.60 22.99 23.38
Resistance 2 (R2) 22.99 22.57 23.02 23.28
Resistance 1 (R1) 22.50 22.31 22.20 22.55 23.19
Pivot Point 21.89 21.89 21.74 21.92 21.89
Support 1 (S1) 21.40 21.47 21.10 21.45 20.81
Support 2 (S2) 20.79 21.21 20.82 20.72
Support 3 (S3) 20.30 20.79 20.63
Support 4 (S4) 20.35